Note: Descriptions are shown in the official language in which they were submitted.
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING BREAST CANCER
The present invention is concerned with the finding that farnesyl protein
transferase
inhibitors are useful for preparing a pharmaceutical composition for treating
advanced
breast cancer.
Oncogenes frequently encode protein components of signal transduction pathways
which lead to- stimulation of cell growth and mitogenesis. Oncogene expression
in
cultured cells leads to cellular transformation, characterized by the ability
of cells to
grow in soft agar and the growth of cells as dense foci lacking the contact
inhibition
exhibited by non-transformed cells. Mutation and/or overexpression of certain
oncogenes is frequently associated with human cancer. A particular group of
oncogenes is known as ras which have been identified in mammals, birds,
insects,
mollusks, plants, fungi and yeasts. The family of mammalian ras oncogenes
consists
of three major members ("isoforms") : H-ras, K-ras and N-ras oncogenes. These
ras
oncogenes code for highly related proteins generically known as p21 ras Once
attached to plasma membranes, the mutant or oncogenic forms of p2lras will
provide a
signal for the transformation and uncontrolled growth of malignant tumor
cells. To
acquire this transforming potential, the precursor of the p21 ras oncoprotein
must
undergo an enzymatically catalyzed farnesylation of the cysteine residue
located in a
carboxyl-terminal tetrapeptide. Therefore, inhibitors of the enzyme that
catalyzes this
modification, farnesyl protein transferase, will prevent the membrane
attachment of
p2lras and block the aberrant growth of ras-transformed tumors. Hence, it is
generally accepted in the art that farnesyl transferase inhibitors can be. v&-
y useful as
anticancer agents for tumors in which ras contributes to transformation.
It has been estimated that as many as 30-40% of human tumours may contain a
ras
mutation, with some tumours, such as colon and lung, showing ras mutations in
around
50% and 90% of tumours, respectively. K-ras and Ha-ras mutations have been
identified in breast cancer tumours, but at low~levels (approximately 5%).
However, although ras mutations are relatively infrequent in breast cancer,
there is
evidence to suggest that the pathways which ras services may still be
deregulated in
breast cancer cells (Clark GJ and Der CJ, Breast Cancer Res. Treat. 1995, 35
(1), 133-
144). Recent identification of many of the components of the ras signal
transduction
pathway has defined a network of protooncogene proteins controlling diverse
signalling
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-2-
events that regulate cell growth and differentiation. Mutations that alter the
function of
any one component of this signal pathway may trigger the same oncogenic events
as a
mutation of ras itself. Moreover, ras-related proteins, such as TC21/R-Ras2,
have been
shown to possess the ability to trigger malignant transformation in MCF-10A
human
breast epithelial cells lines via signalling pathways shared with ras proteins
(Clark G.J.
et al, Oncogene, 1996, 12(1), 169-76). Also, TC21 protein expression was found
to be
greatly elevated in 7 of 9 breast tumour lines when compared to untransformed
MCF-
l0A cells.
Bland et al (Ann. Surg. 1995, 221(6), 706-18) looked at oncogene protein
expression as
prognostic discriminants for breast cancer. Of the individual oncogenes
examined
(c-fos, c-myc, Ha-ras and p53), the presence of Ha-ras and c-fos gave the
greatest
prediction for poor survival.
Breast cancer is the most common female malignancy and the main cause of death
from cancer in women. Each year approximately 30,000 new cases are diagnosed
and
there are nearly 16,000 deaths in the UK; about 1 in 12 women will develop
breast
cancer at some time in their life.
Patients with clinically evident distant metastases are still incurable,
although the
disease may be controlled for periods longer than 5 or 10 years in some
patients.
However the median survival of all patients with metastatic disease is
approximately 2
to 3 years, and the search for additional effective therapies continues.
Currently patients with indolent disease, i.e. disease characterised by the
presence of
bone, soft tissue or non-life threatening visceral metastases are generaily
ff_eated in the
first instance with an endocrine therapy, such as an aromatase inhibitor, anti-
oestrogen
or progestogen. Depending on their response to that therapy, patients may
receive
further endocrine treatment before being considered for chemotherapy. Patients
with
aggressive disease, characterised by widespread symptomatic metastases or
extensive
visceral involvement, will normally be considered for combination therapy,
such as
FEC or CAF, as a more rapid response is desirable in these patients. Patients
who have
oestrogen receptor (ER) negative tumours may also be treated in the first
instance with
chemotherapy, since hormonal therapy is largely ineffective in this group.
WO-97/21701 describes the preparation, formulation and pharmaceutical
properties of
farnesyl protein transferase inhibiting (imidazoly-5-yl)methyl-2-quinolinone
derivatives of formulas (I), (II) and (III), as well as intermediates of
formula (II) and
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-3-
(III) that are metabolized in vivo to the compounds of formula (I). The
compounds of
formulas (I), (II) and (III) are represented by
R3~ R16 R4 R3 R16 R4
R `I=~RS R_~~ ` I =N
R
Z 2
R17 R17
R8 T-R6 I,. I R$ I -R6
~ . .
X N
I Rlq R18 R7 R19 R18 R7
R1
m 01)
R\% 16 R4
/= =N
R2 ~ ,R5
HN
R17
~ I . Rg I .J R6
R19 Rls R7
0
~
the pharmaceutically acceptable acid or base addition salts and the
stereochemically
5 isomeric forms thereof, wherein
the dotted line represents an optional bond;
X is oxygen or sulfur;
Rlis hydrogen, C1_12alkyl, Arl-, Ar2C1_6alkyl, quinolinylCl_6alkyl,
pyridylC1_6alkyl, hydroxyC1-6alkyl, C1_6alkyloxyC1_6alkyl, mono- or
di(C1-6alkyl)aminoC1_6alkyl, aminoC1-6alkyl,
or a radical of formula -Alk1-C(=O)-R9, -A1k1-S(O)-R9 or -A1k1-S(O)2-R9,
wherein Alkl is C1_6alkanediyl,
R9 is hydroxy, C1-6alkyl, C1_6alkyloxy, amino, C1_8alkylamino or
C1-8alkylamino substituted with C1_6alkyloxycarbonyl;
R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano,
C1_6alkyl,
C1-6alkyloxy, hydroxyC1-6alkyloxy, C1_6alkyloxyC1-6al.kyloxy, aminoC1-6alkyl-
oxy, mono- or di(C1-6alkyl)aminoC1_6alkyloxy, Arl, Ar2C1_6alkyl, Ar2oxy,
Ar2C1_6alkyloxy, hydroxycarbonyl, C1_6alkyloxycarbonyl, trihalomethyl,
trihalomethoxy, C2_6alkenyl, 4,4-dimethyloxazolyl; or
when on adjacent positions R2 and R3 taken together may form a bivalent
radical of
formula
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-4-
-O-CH2-O-
-O-CH2-CH2-O- (a-2),
-O-CH=CH- (a-3),
-O-CH2-CH2- (a-4),
-O-CH2-CH2-CH2- (a-5), or
-CH=CH-CH=CH- (a-6);
R4 and R5 each independently are hydrogen, halo, Arl, C1-6alkyl, hydroxyC1-
6alkyl,
C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl,
C1-6alkyloxycarbonyl, C1-6a1ky1S(O)C1-6alkyl or C1-6a1ky1S(O)2C1-6alkyl;
R6 and R7 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-
6alkyloxy,
Ar2oxy, trihalomethyl, C1-6alkylthio, di(C1-6a1ky1)amino, or
when on adjacent positions R6 and R7 taken together may form a bivalent
radical of
formula
-O-CH2-O- (c-1), or
-CH=CH-CH=CH- (c-2);
R8 is hydrogen, C1-6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl,
C1-6alkylcarbonylC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6a1ky1,
carboxyC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)-
aminoC1-6alkyl, imidazolyl, haloC1-6a1ky1, C1-6a1ky1oxyC1-6alkyl,
aminocarbonylC1-6alkyl, or a radical of formula
-O-R10 (b-1),
-S-R 10 (b-2),
-N-R11R12 (b-3),
wherein R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Arl, Ar2C1-6alkyl,
C1-6alkyloxycarbonylC1-6alkyl, or a radical or formula -A1k2-OR13
or -Alk2-NR14R15;
R11 is hydrogen, C1-12alkyl, Arl or Ar2C1-6alkyl;
R12 is hydrogen, C1-6alkyl, C1-16alkylcarbonyl, C1-6alkyloxycarbonyl,
C1-6alkylaminocarbonyl, Arl, Ar2C1-6alkyl, C1-6alkylcarbonyl-
C1-6alkyl, a natural amino acid, Arlcarbonyl,
Ar2C1-6alkylcarbonyl, aminocarbonylcarbonyl,
C1-6alkyloxyCl-6alkylcarbonyl, hydroxy, C1-6alkyloxy,
aminocarbonyl, di(C1-6alkyl)aminoC1-6alkylcarbonyl, amino,
C1-6alkylamino, C1-6alkylcarbonylamino, or a radical or formula -
A1k2-OR13 or -Alk2-NR14R15;
wherein Alk2 is C1-6alkanediyl;
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-5-
R13 is hydrogen, C1-6alky1, C1-6alkylcarbonyl, hydroxy-
C1-6alkyl, Arl or Ar2C1-6alkyl;
R14 is hydrogen, Cl-6alkyl, Arl or Ar2C1-6alkyl;
R15 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Arl or
Ar2C1-6alkyl;
R17 is hydrogen, halo, cyano, Cl-6alkyl, C1-6alkyloxycarbonyl, Arl;
R18 is hydrogen, Cl-6alkyl, C1-6alkyloxy or halo;
R19 is hydrogen or C1-6alkyl;
Arl is phenyl or phenyl substituted with Cl-6alkyl, hydroxy, amino, C1-
6alkyloxy or
halo; and
Ar2 is phenyl or phenyl substituted with Cl-6alkyl, hydroxy, amino, C1-
6alkyloxy or
halo.
WO-97/16443 concerns the preparation, formulation and pharmaceutical
properties of
farnesyl protein transferase inhibiting compounds of formula (IV), as well as
intermediates of formula (V) and (VI) that are metabolized in vivo to the
compounds of
formula (IV). The compounds of formulas (IV), (V) and (VI) are represented by
R3 R16 Rq R3 R16 Rq
R2 I iR5 R2 I iR5
N N
R17 R17
R$ -R6 R$ ~ J R6
X N
R19 R18 R7 N R19 R1s R7
R1
(IV) (V) 20
R3 16 R4
Rz iR5
N
R17
. I . R8 I .J R6
I R19 R18 R7
O-
(VI)
the pharmaceutically acceptable acid or base addition salts and the
stereochemically
isomeric forms thereof, wherein
the dotted line represents an optional bond;
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-6-
X is oxygen or sulfur;
Rl is hydrogen, C1-12alkYl, Arl, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridyl-
Cl-6alkY1, hydroxyC1-6a1kYl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkYl)-
aminoC1-6alkyl, aminoC1-6a1kYl,
or a radical of formula -Alkl-C(=O)-R9, -Alkl-S(O)-R9 or -Alkl-S(O)2-R9,
wherein Alk1 is C1-6alkanediyl,
R9 is hydroxy, C1-6alkyl, C1-6alkyloxy, amino, Cl-galkylamino or
Ci-galkylamino substituted with C1-6alkyloxycarbonyl;
R2 and R3 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl,
C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, amino-
C1-6alkyloxy, mono- or di(C1-6a1ky1)aminoC1-6alkyloxy, Arl, Ar2C1-6alkyl,
Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl,
trihalomethyl, trihalomethoxy, C2-6alkenyl; or
when on adjacent positions R2 and R3 taken together may form a bivalent
radical
of formula
-O-CH2-O- (a-1),
-O-CH2-CH2-O- (a-2),
-O-CH=CH- (a-3),
-O-CH2-CH2- (a-4),
-O-CH2-CH2-CH2- (a-5), or
-CH=CH-CH=CH- (a-6);
R4 and R5 each independently are hydrogen, Arl, C1_6alkyl,
C1_6alkyloxyCt.6alkyl,
C1_6alkyloxy, C1_6alkylthio, amino, hydroxycarbonyl, C1_6alkyloxycarbonyl,
C1_6alkylS(O)C1_6alkyl or C1_6a1ky1S(O)aC1_6alkyl;
R6 and R7 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-
6alkyloxy or
Ar2oxy;
R8 is hydrogen, C1-6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl,
C1{alkyl-
carbonylC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, hydroxy-
carbonylCl-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)-
aminoC1-6alkyl, haloC1-6alkyl, C1-6alkyloxyC1-6alkyl,
aminocarbonylC 1-6alkyl, Arl, Ar2C 1-6alkyloxyC 1-6alkyl,
C 1-6alkylthioC 1-6alkyl;
R10 is hydrogen, C1-6alkyl, C1-6alkyloxy or halo;
R11 is hydrogen or C1-6alkyl;
Arl is phenyl or phenyl substituted with C1-6alkyl,hydroxy,amino,C1-6alkyloxy,
or
halo;
Ar2 is phenyl or phenyl substituted with C1-6a1ky1,hydroxy,amino,C1-6alkyloxy
or
halo.
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-7-
WO-98/40383 concerns the preparation, formulation and pharmaceutical
properties of
famesyl protein transferase inhibiting compounds of formula (VII)
R2 R4
Rl R3
/ / .
R6
R5 (VII)
X N
A
the pharmaceutically acceptable acid additioii salts and the stereochemically
isomeric
forms thereof, wherein
the dotted line represents an optional bond;
X is oxygen or sulfur;
-A- is a bivalent radical of formula
-CH=CH- (a-1), -CH2-S- (a-6),
-CH2-CH2- (a-2), -CH2-CH2-S- (a-7),
-CH2-CH2-CH2- (a-3), -CH=N- (a-8),
-CH2-O- (a-4), -N=N- (a-9), or
-CH2-CH2-O- (a-5), -CO-NH- (a-10);
wherein optionally one hydrogen atom may be replaced by C1-4alkyl or Arl;
R1 and R2 each independently are hydrogen, hydroxy, halo, cyano, C1_.6alkyl,
trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy,
hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl,
aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar2,
Ar2-C1-6alkyl, Ar2-oxy, Ar2-C1-6alkyloxy; or when on adjacent positions R1 and
R2 taken together may form a bivalent radical of formula
-O-CH2-O- (b-1),
-O-CH2-CH2-O- (b-2),
-O-CH=CH- (b-3),
-O-CH2-CH2- (b-4),
-O-CH2-CH2-CH2- (b-5), or
-CH=CH-CH=CH- (b-6);
R3 and R4 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-
6alkyloxy,
Ar3-oxy, C1-6alkylthio, di(C1-6alkyl)amino, trihalomethyl, trihalomethoxy, or
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-8-
when on adjacent positions R3 and R4 taken together may form a bivalent
radical
of formula
-O-CH2-O- (c-i),
-O-CH2-CH2-O- (c-2), or
-CH=CH-CH=CH- (c-3);
R5 is a radical of formula
- `j (d-1), J R13 (d-2),
N
R13 R14
wherein R13 is hydrogen, halo, Ar4, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxy-
C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, C1-6alkyloxy-
carbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;
R14is hydrogen, C1-6alkyl or di(C1-4alkyl)aminosulfonyl;
R6 is hydrogen, hydroxy, halo, C1-6a1ky1, cyano, haloC1-6alkyl,
hydroxyC1-6alkyl, cyanoC1-6alkyl, aminoC1-6alkyl, C1-6alkyloxyC1-6alkyl,
C1-6a1ky1thioC1-6alkyl, aminocarbonylCl-6alkyl,
C1-6alkyloxycarbonylC1-6alkyl, C1-6alkylcarbonyl-C1-6alkyl,
C1-6alkyloxycarbonyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, Ar5,
Ar5-C 1-6alkyloxyC 1-6alkyl; or a radical of formula
-O-R7 (e-1),
-S-R7 (e-2),
-N-R8R9 (e-3),
wherein R7 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar6, Ar6-C1-6alkyl,
C1-6alkyloxycarbonylC1-6alkyl, or a radical of formula. -.Alk-0R10
or -Alk-NR11R12;
R8 is hydrogen, C1-6alkyl, Ar7 or Ar7-C1-6alkyl;
R9 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl,
C1-6alkylaminocarbonyl, Ar8, Ar8-C1-6alkyl, C1-6alkylcarbonyl-
C1-6alkyl, Ar8-carbonyl, Ar8-C1-6alkylcarbonyl, aminocarbonyl-
carbonyl, C1-6alkyloxyC1-6alkylcarbonyl, hydroxy, C1-6alkyloxy,
aminocarbonyl, di(C1-6alkyl)aminoC1-6alkylcarbonyl, amino,
C1-6alkylamino, C1-6alkylcarbonylamino,
or a radical or formula -Alk-OR10 or -Alk-NR11R12;
wherein Alk is C1-6alkanediyl;
R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, hydroxy-
C1-6alkyl, Ar9 or Ar9-C1-6alkyl;
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-9-
Rll is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar10 or
Ar10-C1-6alkYl;
R12 is hydrogen, C1-6alkyl, Arl l or Ar11-C1-6alkyl; and
Arl to Arl l are each independently selected from phenyl; or phenyl
substituted
with halo, C1-6alkyl, C1-6alkyloxy or trifluoromethyl.
WO-98/49157 concerns the preparation, formulation and pharmaceutical
properties of
farnesyl protein transferase inhibiting compounds of formula (VIII)
2 R4
R: . Rs
6 (VIIEI)
X
Rs 9
the pharmaceutically acceptable acid addition salts and the stereochemically
isomeric
forms thereof, wherein
the dotted line represents an optional bond;
X is oxygen or sulfur;
Rl and R2 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl,
trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy,
hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl,
aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Arl,
Ar1C1-6alkY1, Arloxy or Ar1C1-6alkyloxy;
R3 and R4 each independently are hydrogen, halo, cyano, C1-6alkyl,
C1_6alkyloxy,
Arloxy, C1-6alkylthio, di(C1-6alkyl)amino, trihalomethyl or trihalomethoxy;
R5 is hydrogen, halo, C1-6alkyl, cyano, haloCl-6alkyl, hydroxyC1-6alkyl,
cyanoC1-6alkyl, aminoCl-6alkyl, C1-6alkyloxyC1-6alkyl,
C1-6alkylthioC1-6alkyl, aminocarbonylCl-6alkYl,
C1-6alkyloxycarbonylC1-6alkyl, C1-6alkylcarbonyl-C1-6alkyl,
C1-6alkyloxycarbonyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, Arl,
Ar1C1-6alkYloxyC1-6alkyl; or a radical of formula
-O-R10 (a-1),
-S-R10 (a-2),
-N-R11R12 (a-3),
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-10-
wherein R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Arl, Ar1C1-6alkyl,
C1-6alkyloxycarbonylC1-6alkyl, or a radical of formula -Alk-OR13
or -AIk-NR14R15;
R11 is hydrogen, C1-6alkyl, Arl or Ar1C1-6alkyl;
R12 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl,
C1-6alkylaminocarbonyl, Arl, Ar1C1-6alkyl, C1-6alkylcarbonyl-
C1-6alkyl, Arlcarbonyl, Ar1C1-6alkylcarbonyl, aminocarbonyl-
carbonyl, C1-6alkyloxyC1-6alkylcarbonyl, hydroxy, C1-6alkyloxy,
aminocarbonyl, di(C1-6alkyl)aminoC1-6alkylcarbonyl, amino,
C1-6alkylamino, C1-6alkylcarbonylamino,
or a radical or formula -Alk-OR13 or -Alk-NR14R15;
wherein Alk is C1-6alkanediyl;
R13 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, hydroxy-
C1-6alkyl, Arl or Ar1C1-6alkyl;
R14 is hydrogen, Ci-6alkyl, Arl or Ar1Ci-6alkyl;
R15 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Arl or
Ar1C 1-6alkyl;
R6 is a radical of formula
N ~ N 16
- ~\J (b-1), J R (b-2),
N
R16 Ri7
wherein R16is hydrogen, halo, Arl, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxy-
C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino,
C1-6alkyloxycarbonyl, C1-6alkylthioC1-6alkyl,
C1-6a1ky1S(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;,
R17is hydrogen, Cl-6alkyl or di(C1-4alkyl)aminosulfonyl;
R7 is hydrogen or Cl-6alkyl provided that the dotted line does not represent a
bond;
R8 is hydrogen, C1-6alkyl or Ar2CH2 or Het1CH2;
R9 is hydrogen, C1-6alkyl, C1-6alkyloxy or halo; or
R8 and R9 taken together to form a bivalent radical of formula
-CH=CH- (c-1),
-CH2-CH2- (c-2),
-CH2-CH2-CH2- (c-3),
-CH2-O- (c-4), or
-CH2-CH2-O- (c-5);
Arl is phenyl; or phenyl substituted with 1 or 2 substituents each
independently
selected from halo, C1-6alkyl, C1-6alkyloxy or trifluoromethyl;
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-11-
Ar2 is phenyl; or phenyl substituted with 1 or 2 substituents each
independently
selected from halo, C1-6alkyl, C1-6alkyloxy or trifluoromethyl; and
Hetl is pyridinyl; pyridinyl substituted with 1 or 2 substituents each
independently
selected from halo, C1-6alky1, CI-6alkyloxy or trifluoromethyl.
WO-00/39082 concerns the preparation, formulation and pharmaceutical
properties of
farnesyl protein transferase inhibiting compounds of formula (IX)
(Rl)r (RZ)ccRR3
YZ.Y (IX)
XN s
(R )c .
X2. X3
or the pharmaceutically acceptable acid addition salts and the
stereochemically
isomeric forms thereof, wherein
=X1-X2-X3- is a trivalent radical of formula
=N-CR6=CR7- (x-1), =CR6-CR7=CR8- (x-6),
=N-N=CR6- (x-2), =CR6-N=CR7- (x-7),
=N-NH-C(=O)- (x-3), =CR6-NH-C(=O)- (x-8), or
=N-N=N- (x-4), =CR6-N=N- (x-9);
=N-CR6 =N- (x-5),
wherein each R6, R7 and R8 are independently hydrogen, C1_4alkyl, hydroxy,
Cl-4alkyloxy, aryloxy, Cl-4alkyloxycarbonyl, hydroxyCl-4alkyl,
C1-4alkyloxyC1_4alkyl, mono- or di(Cl_4alkyl)aminoCl_4alkyl, cyan~~o--ami.no,
thio,
Cl-4alkylthio, arylthio or aryl;
>YI-Ya- is a trivalent radical of formula
>CH-CHR9- (y-1),
>C=N- (y-2),
>CH-NR9- (y-3),or
>C=CR9- (y-4);
wherein each R9 independently is hydrogen, halo, halocarbonyl, aminocarbonyl,
hydroxyCl-4alkyl, cyano, carboxyl, C1_4alkyl, Cl-4alkyloxy,
C1-4alkyloxyC1_4alkyl, Cl-4alkyloxycarbonyl, mono- or di(Cl_4alkyl)amino,
mono- or di(Cl_4alkyl)aminoCl_4alkyl, aryl;r and s are each independently 0,
1, 2, 3, 4 or 5;
tis0,1,2or3;
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-12-
each Rl and R2 are independently hydroxy, halo, cyano, C1-6alkyl,
trihalomethyl,
trihalomethoxy, Ca-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, Cl-6alkylthio,
C1-6alkyloxyCl-6alkyloxy, C1_6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or
di(Cl-6alkyl)amino, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, aryl,
ary1C1_6alkyl,
aryloxy or arylCi-6alkyloxy, hydroxycarbonyl, Ci.6alkyloxycarbonyl,
aminocarbonyl, aminoCl-6alkyl, mono- or di(C1-6alkyl)aminocarbonyl, mono- or
di(C1-6alkyl)aminoC1-6alkyl; or
two R' or R2 substituents adjacent to one another on the phenyl ring may
independently
form together a bivalent radical of formula
-O-CHZ-O- (a-1),
-O-CHa-CH2-O- (a-2),
-O=CH=CH- (a-3),
-O-CH2-CH2- (a-4),
-O-CHa-CH2- CH2- (a-5), or
-CH=CH-CH=CH- (a-6);
R3 is hydrogen, halo, C1_6alkyl, cyano, haloC1-6alkyl, hydroxyC1_6alkyl,
cyanoCl-6alkyl, aminoCl.6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl,
aminocarbonylCl.6alkyl, hydroxycarbonyl, hydroxycarbonylC1-6alkyl,
C1-6alkyloxycarbonylCl-6alkyl, C1-6alkylcarbonylC1-6alkyl, C1-
6alkyloxycarbonyl,
aryl, ary1C1-6alkyloxyCl-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl;
or a radical of formula
-O-R10
-S-R10 (b-2),
-NRi iRi2 (b-3),
wherein R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, aryl, ary1C1-6alkyl,
C1-6alkyloxycarbonylC1-6alkyl, or a radical of formula -Alk'-OR13 or
-Alk-NR14R15;
R" is hydrogen, Cl-6alkyl, aryl or arylC1-6alkyl;
R12 is hydrogen, C1-6alkyl, aryl, hydroxy, amino, C1-6alkyloxy,
C1-6alkylcarbonylC1-6alkyl, arylCl-6alkyl, C1-6alkylcarbonylamino,
mono- or di(Cl-6alkyl)amino, C1-6alkylcarbonyl, aminocarbonyl,
arylcarbonyl, haloCl-6alkylcarbonyl, arylCl-6alkylcarbonyl,
Cl -6alkyloxycarbonyl,
C1-6alkyloxyCl-6alkylcarbonyl, mono- or di(C1-6alkyl)aminocarbonyl
wherein the alkyl moiety may optionally be substituted by one or more
substituents independently selected from aryl or C1-3alkyloxycarbonyl,
aminocarbonylcarbonyl, mono- or di(C1-6alkyl)aminoCl-6alkylcarbonyl,
or a radical or formula -Alk-OR13 or -Alk-NRI4RI5 ;
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-13-
wherein Alk is C1-6alkanediyl;
R13 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, hydroxyC1-6alkyl, aryl or
ary1C1-6alkyl;
R14 is hydrogen, C1-6alkyl, aryl or arylC1_6alkyl;
R15 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, aryl or arylC1-6alkyl;
R4 is a radical of formula
-N~ j (c-1), / J R16 (c-2),
\ 16 N
R17
wherein R16 is hydrogen, halo, aryl, Ci-6alkyl, hydroxyC1-6alkyl, C1-
6alkyloxyCl-6alkyl,
C1-6alkyloxy, C1-6alkylthio, amino, mono- or di(Cl-4alkyl)amino,
hydroxycarbonyl, Cl-6alkyloxycarbonyl, Ci-6a1ky1thioC1_6alkyl,
Ci-6a1ky1S(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;
R16 may also be bound to one of the nitrogen atoms in the imidazole ring of
formula (c-1) or (c-2), in which case the meaning of R16 when bound to the
nitrogen is limited to hydrogen, aryl, Cl-6alkyl, hydroxyC1_6allcyl,
C1-6alkyloxyC1_6alkyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)Cl-6alkyl or
C 1-6alkylS (O)2C i-6alkyl;
R17 is hydrogen, Ci-6alkyl, C1.6alkyloxyC1-6alkyl, arylC1_6alkyl,
trifluoromethyl or di(C1-4alkyl)aminosulfonyl;
RS is C1-6alkyl , C1-6alkyloxy or halo;
aryl is phenyl, naphthalenyl or phenyl substituted with 1 or more substituents
each
independently selected from halo, C1.6alkyl, C1_6alkyloxy or trifluoromethyl .
Other useful farnesyl protein transferase inhibitors include Arglabin
(i.e.l(R)-10-
epoxy-5(S),7(S)-guaia-3(4),11(13)-dien-6,12-olide descibed in WO-98/28303
(NuOncology Labs); perrilyl alcohol described in WO-99/45912 (Wisconsin
Genetics);
SCH-66336, i.e. (+)-(R)-4-[2-[4-(3,10-dibromo-8-chloro-5,6-dihydro-11H-
benzo [5,6]cyclohepta[ 1,2-b]pyridin-11-yl)piperidin-1-yl]-2-
oxoethyl]piperidine-l-
carboxamide, described in U.S. Patent No. 5874442 (Schering); L778123, i.e. 1-
(3-
chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone,
described in
WO-00/01691 (Merck); compound 2(S)-[2(S)-[2(R)-amino-3-mercapto]propylamino-
3(S)-methyl]-pentyloxy-3-phenylpropionyl-methionine sulfone described in WO-
94/10138 (Merck); and BMS 214662, i.e. (R)-2,3,4,5-tetrahydro-l-(IH-imidazol-4-
ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulphonyl)-1H-1,4-benzodiazapine-7-
carbonitrile, described in WO 97/30992 (Bristol Myers Squibb) and Pfizer
compounds
(A) and (B) described in WO-00/12498 and WO-00/12499:
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-14-
ci ci
- ~ ~
Hc' o~N~
NH2 NH
Z
N
O N / H3C
CH
3 CH3
(A) (B)
Unexpectedly, we have now found that a farnesyl protein transferase inhibitor
has
clinical activity in advanced breast cancer. This effect is especially
surprising as
treatment with the farnesyl protein transferase inhibitor results in shrinkage
of the
tumor rather than simply delaying tumor progression. This effect is in
contrast to the
suggestion in Rowinsky et al, Journal of Clinical Oncology, Vol 17, No. 11
(November), 1999, pages 3631-3652 at page 3646 that tumor growth inhibition or
"cytostasis" may be the principal therapeutic effect of FTase inhibitors.
The present invention is concerned with the use of at least a farnesyl protein
transferase
inhibitor for the preparation of a pharmaceutical composition for treating
advanced
breast cancer. The term "advanced breast cancer" is used herein to denote
breast cancer
which has not responded to previous treatment, or which has recurred following
such
treatment, and also breast cancer in patients who present with metastatic
disease at
diagnosis.
The present invention also concerns a method of treating advanced breast
cancer in a
mammal, particularly a woman, comprising the step of administering a
therapeutically
effective amount of a farnesyl protein tranferase inhibitor to said mammal.
In particular, the present invention is concerned with the use of at least a
farnesyl
protein transferase inhibitor for the preparation of a pharmaceutical
composition for
treating advanced breast cancer, wherein said farnesyl protein transferase
inhibitor is a
compound of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX)
above, more
particularly a compound of formula (I), (II) or (III):
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-15-
R3 R16 R4 RR16 R4
R2 ~=I=NRS RZ r~ ~/. S
R17 R17
\ \ = \ \
Rs R8 RG
X R R19 R18 R7 R19 R18 R7
1
m ~m
R\ 16 Rq
-I ~
Ra Rs
R17
+ R8 Rs
N
I R q R18 R7
0"
~m)
the pharmaceutically acceptable acid or base addition salts and the
stereochemically
isomeric forms thereof, wherein
the dotted line represents an optional bond;
X is oxygen or sulfur;
Rl is hydrogen, Cl-12alkyl, Arl, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridyl-
C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)-
aminoC1-6alkyl, aminoC1-6alkyl,
or a radical of fonnula -Alk1-C(=O)-R9, -Alkl-S(O)-R9 or -Alkl-S(O)2-R9,
wherein Alkl is C1-6alkanediyl,
R9 is hydroxy, C1_6alkyl, C1-6alkyloxy, amino, C1-8alkylamino or
Cl-galkylamino substituted with C1-6alkyloxycarbonyl;
R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-
6alkyl,
Cl-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy,
aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Arl,
Ar2C1-6alkyl, Ar2oxy, Ar2Cl-6alkyloxy, hydroxycarbonyl,
Cl-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, 4,4-
dimethyloxazolyl; or
when on adjacent positions R2 and R3 taken together may form a bivalent
radical
of formula
-O-CH2-O-
-O-CH2-CH2-O- (a-2),
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-16-
-O-CH=CH- (a-3),
-O-CH2-CH2- (a-4),
-O-CH2-CH2-CH2- (a-5), or
-CH=CH-CH=CH (a-6);
R4 and R5 each independently are hydrogen, halo, Arl, C1-6alkyl, hydroxyC1-
6alkyl,
C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl,
C1-6alkyloxycarbonyl, Cl-6alkylS(O)C1-6alkyl or C1-6a1ky1S(O)2C1-6a1ky1;
R6 and R7 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-
6alkyloxy,
Ar2oxy, trihalomethyl, C1-6alkylthio, di(C1-6alkyl)amino, or
when on adjacent positions R6 and R7 taken together may form a bivalent
radical
of formula
-O-CH2-O- (c-1), or
-CH=CH-CH=CH- (c-2);
R8 is hydrogen, C1..6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl,
C1-6alkylcarbonylCi-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylCl-6alkyl,
carboxyC1-6alkyl, hydroxyCl-6alkyl, aminoC1-6alkyl, mono- or
di(C1-6alkyl)aminoC1-6alkyl, imidazolyl, haloC1-6alkyl,
C1-6alkyloxyC1-6alkyl, aminocarbonylC1-6alkyl, or a radical of formula
-O -R10 (b-1),
-S-R10 (b-2),
-N-R11R12 (b-3),
wherein R10is hydrogen, C1-6a1ky1, C1-6alkylcarbonyl, Arl, Ar2C1-6alkyl,
C1_6alkyloxycarbonylC1-6alkyl, or a radical or formula -Alk2-OR13
or -Alk2-NR14R15;
Rl l is hydrogen, C1-12alkyl, Arl or Ar2C1-6alkyl;
R12is hydrogen, C1-6alkyl, Cl-16alkylcarbonyl, Cl-6alkyloxycarbonyl,
C1-6alkylaminocarbonyl, Arl, Ar2C1-6alkyl, C1-6alkylcarbonyl-
C1-6alkyl, a natural amino acid, Arlcarbonyl,
Ar2C1_6alkylcarbonyl, aminocarbonylcarbonyl,
C1-6alkyloxyC1-6alkylcarbonyl, hydroxy, C1-6a1ky1oxy,
aminocarbonyl, di(C1-6alkyl)aminoC1-6alkylcarbonyl, amino,
C1-6alkylamino, C1-6alkylcarbonylamino,
or a radical or formula -Alk2-OR13 or -Alk2-NR14R15;
wherein Alk2 is C1-6alkanediyl;
R13 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, hydroxy-
C1-6alkyl, Arl or Ar2C1-6alkyl;
R14 is hydrogen, C1-6alkyl, Arl or Ar2C1-6alkyl;
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-17-
R15 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Arl or
Ar2C1-6alkyl;
R17is hydrogen, halo, cyano, Cl-6alkyl, C1-6alkyloxycarbonyl, Arl;
R18is hydrogen, C1-6alkyl, C1-6alkyloxy or halo;
R19 is hydrogen or C1-6alkyl;
Arl is phenyl or phenyl substituted with Cl-6alkyl, hydroxy, amino, C1-
6alkyloxy or
halo; and
Ar2 is phenyl or phenyl substituted with Cl-6alkyl, hydroxy, amino, C1-
6alkyloxy or
halo.
In Formulas (n, (II) and (III), R4 or R5 may also be bound to one of the
nitrogen atoms
in the imidazole ring. In that case the hydrogen on the nitrogen is replaced
by R4 or R5
and the meaning of R4 and R5 when bound to the nitrogen is limited to
hydrogen, Arl,
Cl-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC.1-6alkyl, C1-6alkyloxycarbonyl,
C1-6a1ky1S(O)C1-6alkyl, C1-6a1ky1S(O)2C1-6a1ky1.
Preferably the substituent R18 is situated on the 5 or 7 position of the
quinolinone
moiety and substituent R19 is situated on the 8 position when R18 is on the 7-
position.
Interesting compounds are these compounds of formula (I) wherein X is oxygen.
Also interesting compounds are these compounds of formula (I) wherein the
dotted line
represents a bond, so as to form a double bond.
Another group of interesting compounds are those compounds of formula (I)
wherein
R1 is hydrogen, Cl-6alkyl, C1-6alkyloxyC1-6alkyl; di(C1-6alkyl)aminoC1-6alkyl,
or a
radical of formula -A1k1-C(=O)-R9, wherein Alkl is methylene and R9 is
C1-8alkylamino substituted with C1-6alkyloxycarbonyl.
Still another group of interesting compounds are those compounds of formula
(I)
wherein R3 is hydrogen or halo; and R2 is halo, C1-6alkyl, C2-6alkenyl, C1-
6alkyloxy,
trihalomethoxy or hydroxyCl-6alkyloxy.
A further group of interesting compounds are those compounds of formula (I)
wherein
R2 and R3 are on adjacent positions and taken together to form a bivalent
radical of
formula (a-1), (a-2) or (a-3).
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-18-
A still further group of interesting compounds are those compounds of formula
(I)
wherein R5 is hydrogen and R4 is hydrogen or C1-6alkyl.
Yet another group of interesting compounds are those compounds of formula (I)
wherein R7 is hydrogen; and R6 is C1-6alkyl or halo, preferably chloro,
especially
4-chloro.
A particular group of compounds are those compounds of formula (I) wherein R8
is
hydrogen, hydroxy, haloC1-6alkyl, hydroxyC1-6alkyl, cyanoCl-6alkyl, C1-
6alkyloxy-
carbonylCl-6alkyl, imidazolyl, or a radical of formula -NR11R12 wherein R11 is
hydrogen or C1-12a1ky1 and R12 is hydrogen, C1-6alkyl, C1-6alkyloxy, hydroxy,
C1-6alkyloxyC1-6alkylcarbonyl, or a radical of formula -Alk2-OR13 wherein R13
is
hydrogen or C1-6alkyl.
Preferred compounds are those compounds wherein Rl is hydrogen, C1-6alkyl,
C1-6alkyloxyC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl, or a radical of formula
-Alkl-C(=O)-R9, wherein Alkl is methylene and R9 is C1-galkylamino substituted
with C1-6alkyloxycarbonyl; R2 is halo, C1-6alkyl, C2-6alkenyl, C1-6alkyloxy,
trihalomethoxy, hydroxyC1-6alkyloxy or Arl; R3 is hydrogen; R4 is methyl bound
to
the nitrogen in 3-position of the imidazole; R5 is hydrogen; R6 is chloro; R7
is
hydrogen; R8 is hydrogen, hydroxy, haloC1-6alkyl, hydroxyC1-6alkyl,
cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, imidazolyl, or a radical of
formula -
NR11R12 wherein R11 is hydrogen or C1-12alkyl and R12 is hydrogen, C1-6alkyl,
Ci-6alkyloxy, Cl-6alkyloxyCi-6alkylcarbonyl, or a radical of formula -Alk2-
OR13
wherein R13 is C1-6alkyl; R17 is hydrogen and R18 is hydrogen.
Most preferred compounds are
4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-lH-imidazol-5-
yl)methyl]-
1-methyl-2(1H)-quinolinone,
6-[amino(4-chlorophenyl)-1-methyl-lH-imidazol-5-ylmethyl]-4-(3-chlorophenyl)-
1-methyl-2(1H)-quinolinone;
6-[(4-chlorophenyl)hydroxy(1-methyl-lH-imidazol-5-yl)methyl]-4-(3-
ethoxyphenyl)-
1-methyl-2(1H)-quinolinone;
6-[(4-chlorophenyl)(1-methyl-lH-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-1-
methyl-2(1H)-quinolinone monohydrochloride.monohydrate;
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-19-
6-[amino(4-chlorophenyl)(1-methyl-1 H-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-
1-
methyl-2(1H)-quinolinone,
6-amino(4-chlorophenyl)(1-methyl-lH-imidazol-5-yl)methyl]-1-methyl-4-(3-
propylphenyl)-2(1H)-quinolinone; a stereoisomeric form thereof or a
pharmaceutically
acceptable acid or base addition salt; and
(+)-6-[amino(4-chlorophenyl)(1-methyl-lH-imidazol-5-yl)methyl]-4-(3-
chlorophenyl)-
1-methyl-2(1H)-quinolinone (Compound 75 in Table 1 of the Experimental part of
WO-97/21701); or a pharmaceutically acceptable acid addition salt thereof. The
latter
compound is especially preferred.
Further preferred embodiments of the present invention include compounds of
formula
(IX) wherein one or more of the following restrictions apply:
==X1-X2-X3 is a trivalent radical of formula (x-1), (x-2), (x-3), (x-4) or (x-
9) wherein
each R6 independently is hydrogen, C1_4alkyl, C1_4alkyloxycarbonyl, amino or
aryl
and R7 is hydrogen;
=>Yl-Y2- is a trivalent radical of formula (y-1), (y-2), (y-3), or (y-4)
wherein each R9
independently is hydrogen, halo, carboxyl, C1_4alkyl or C1_4alkyloxycarbonyl;
= r is 0, 1 or 2;
= sis Oorl;
= tis0;
= R' is halo, C1_6alkyl or two Rl substituents ortho to one another on the
phenyl ring
may independently form together a bivalent radical of formula (a-1);
= R2 is halo;
= R3 is halo or a radical of formula (b-1) or (b-3) wherein
R10 is hydrogen or a radical of formula -Alk-OR'3.
Ril is hydrogen;
R12 is hydrogen, C1_6alkyl, C1_6alkylcarbonyl, hydroxy, Ct_6alkyloxy or mono-
or
di(C1_6alkyl)aminoC 1_6alkylcarbonyl;
Alk is C1_6alkanediyl and R13 is hydrogen;
= R4 is a radical of formula (c-1) or (c-2) wherein
R16 is hydrogen, halo or mono- or di(Cl-4alkyl)amino;
R17 is hydrogen or C1_6alkyl;
= aryl is phenyl.
A particular group of compounds consists of those compounds of formula (IX)
wherein
=X1-X2-X3 is a trivalent radical of formula (x-1), (x-2), (x-3), (x-4) or (x-
9), >Yl-Y2 is
a trivalent radical of formula (y-2), (y-3) or (y-4), r is 0 or 1, s is 1, t
is 0, R' is halo,
C(l-4)alkyl or forms a bivalent radical of formula (a-1), R2 is halo or
C1_4alkyl, R3 is
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-20-
hydrogen or a radical of formula (b-1) or (b-3), R4 is a radical of formula (c-
1) or (c-2),
R6 is hydrogen, C1.4a1ky1 or phenyl, R7 is hydrogen, R9 is hydrogen or Cl-
4alkyl, R10 is
hydrogen or -Alk-OR13, R" is hydrogen and R12 is hydrogen or
Cl-6alkylcarbonyl and R13 is hydrogen;
Preferred compounds are those compounds of formula (IX) wherein =X1-X2-X3 is a
trivalent radical of formula (x-1) or (x-4), >Yl-Y2 is a trivalent radical of
formula (y-
4), r is 0 or 1, s is 1, t is 0, R' is halo, preferably chloro and most
preferably 3-chloro,
R2 is halo, preferably 4-chloro or 4-fluoro, R3 is hydrogen or a radical of
formula (b-1)
or (b-3), R4 is a radical of formula (c-1) or (c-2), R6 is hydrogen, R7 is
hydrogen, R9 is
hydrogen, R10 is hydrogen, Rll is hydrogen.and R12 is hydrogen;
Other preferred compounds are those compounds of formula (IX) wherein =X'-X2-
X3
is a trivalent radical of formula (x-2), (x-3) or (x-4) >Yl-Y2 is a trivalent
radical of
formula (y-2), (y-3) or (y-4), r and s are 1, t is 0, Rl is halo, preferably
chloro, and most
preferably 3-chloro or Rl is Cl-4alkyl, preferably 3-methyl, R 2 is halo,
preferably
chloro, and most preferably 4-chloro, R3 is a radical of formula (b-1) or (b-
3), R4 is a
radical of formula (c-2), R6 is Cl-4alkyl, R9 is hydrogen, R10 and Rl l are
hydrogen and
Rl2 is hydrogen or hydroxy.
The most preferred compounds of formula (IX) are
7-[(4-fluorophenyl)(1H-imidazol-1-yl)methyl]-5-phenylimidazo [ 1,2-
a]quinoline;
a-(4-chlorophenyl)-a-(1-methyl-lH-imidazol-5-yl)-5-phenylimidazo[ 1,2-
a]quinoline-
7-methanol;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-(1-methyl-lH-imidazol-5-yl)-
imidazo[1,2-
a]quinoline-7-methanol;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-(1-methyl-1 H-imidazol-5-yl)imidazo [
1,2-
a] quinoline-7-methanamine;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-(1-methyl-1 H-imidazol-5-yl)tetrazolo
[ 1, 5-
a]quinoline-7-methanamine;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-1-methyl-a-(1-methyl-1 H-imidazol-5-yl)-
1,2,4-
triazolo [4,3-a] quinoline-7-methanol;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-(1-methyl-1 H-imidazol-5-yl)tetrazolo
[ 1,5-
a]quinoline-7-methanamine;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-(1-methyl-lH-imidazol-5-
yl)tetrazolo[1,5-
a]quinazoline-7-methanol; 5-(3-chlorophenyl)-a-(4-chlorophenyl)-4,5-dihydro-a-
(1-
methyl-1 H-imi dazol-5-yl)tetrazolo [ 1, 5-a] quinazoline-7 -meth anol;
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-21-
5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-(1-methyl-lH-imidazol-5-
yl)tetrazolo[1,5-
a] quinazoline-7-methanamine;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-N-hydroxy-a-(1-methyl-lH-imidazol-5-
yl)tetrahydro [ 1,5-a] quinoline-7-methanamine;
a-(4-chlorophenyl)-a-(1-methyl-lH-imidazol-5-yl)-5-(3-
methylphenyl)tetrazolo[1,5-
a]quinoline-7-methanamine; the pharmaceutically acceptable acid addition salts
and the
stereochemically isomeric forms thereof.
5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-(1-methyl-lH-imidazol-5-
yl)tetrazolo[1,5-
a]quinazoline-7-methanamine, especially the (-) enantiomer, and its
pharmaceutically
acceptable acid addition salts are especially preferred.
As used in the foregoing definitions and hereinafter halo defines fluoro,
chloro, bromo
and iodo; C1-6alkyl defines straight and branched chained saturated
hydrocarbon
radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl,
propyl,
butyl, pentyl, hexyl and the like; C1-8alkyl encompasses the straight and
branched
chained saturated hydrocarbon radicals as defined in C1-6alkyl as well as the
higher
homologues thereof containing 7 or 8 carbon atoms such as, for example heptyl
or
octyl; C1-12alkyl again encompasses C1-galkyl and the higher homologues
thereof
containing 9 to 12 carbon atoms, such as, for example, nonyl, decyl, undecyl,
dodecyl;
C1-16alky1 again encompasses C1-12alkyl and the higher homologues thereof
containing 13 to 16 carbon atoms, such as, for example, tridecyl, tetradecyl,
pentedecyl
and hexadecyl; C2_6alkenyl defines straight and branched chain hydrocarbon
radicals
containing one double bond and having from 2 to 6 carbon atoms such as, for
example,
ethenyl, 2-propenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl,
and the
like; C1-6alkanediyl defines bivalent straight and branched chained satufited-
hydrocarbon radicals having from 1 to 6 carbon atoms, such as, for example,
methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl,
1,6-hexanediyl and the branched isomers thereof. The term "C(=O)" refers to a
carbonyl group, "S(O)" refers to a sulfoxide and "S(O)2" to a sulfon. The term
"natural
amino acid" refers to a natural amino acid that is bound via a covalent amide
linkage
formed by loss of a molecule of water between the carboxyl group of the amino
acid
and the amino group of the remainder of the molecule. Examples of natural
amino
acids are glycine, alanine, valine, leucine, isoleucine, methionine, proline,
phenylanaline, tryptophan, serine, threonine, cysteine, tyrosine, asparagine,
glutamine,
aspartic acid, glutamic acid, lysine, arginine, histidine.
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-22-
The pharmaceutically acceptable acid or base addition salts as mentioned
hereinabove
are meant to comprise the therapeutically active non-toxic acid and non-toxic
base
addition salt forms which the compounds of formulas (I), (II), (III), (IV),
(V), (VI),
(VII), (VIII) or (IX) are able to form. The compounds of formulas (1), (II),
(III), (IV),
(V), (VI), (VII), (VIII) or (IX) which have basic properties can be converted
in their
pharmaceutically acceptable acid addition salts by treating said base form
with an
appropriate acid. Appropriate acids comprise, for example, inorganic acids
such as
hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric;
phosphoric and
the like acids; or organic acids such as, for example, acetic, propanoic,
hydroxyacetic,
lactic, pyruvic, oxalic, malonic, succinic (i.e. butanedioic acid), maleic,
fumaric, malic,
tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-
toluenesulfonic,
cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
The compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or
(IX) which
have acidic properties may be converted in their pharmaceutically acceptable
base
addition salts by treating said acid form with a suitable organic or inorganic
base.
Appropriate base salt forms comprise, for example, the ammonium salts, the
alkali and
earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium,
calcium
salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-
glucamine,
hydrabamine salts, and salts with amino acids such as, for example, arginine,
lysine and
the like.
The terms acid or base addition salt also comprise the hydrates and the
solvent addition
forms which the compounds of formulae (I), (II), (III), (IV), (V), (VI),
(VIl), (VIII) or
(IX) are able to form. Examples of such forms are e.g. hydrates, alcoholates
and the
like.
The term stereochemically isomeric forms of compounds of formulae (I), (II),
(III),
(IV), (V), (VI), (VII), (VIII) or (IX), as used hereinbefore, defines all
possible
compounds made up of the same atoms bonded by the same sequence of bonds but
having different three-dimensional structures which are not interchangeable,
which the
compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX)
may possess.
Unless otherwise mentioned or indicated, the chemical designation of a
compound
encompasses the mixture of all possible stereochemically isomeric forms which
said
compound may possess. Said mixture may contain all
diastereomers and/or enantiomers of the basic molecular structure of said
compound.
All stereochemically isomeric forms of the compounds of formulae (I), (Il),
(III), (IV),
CA 02396865 2008-03-27
WO 01/56552 PCT/EP01/01032
-23-
(V), (VI), (VII), (VIIl) or (IX) both in pure form or in admixture with each
other are
intended to be embraced within the scope of the present invention.
= Some of the compounds of fornaulae (1), (11), (III), (IV), (V), (VI), (VII),
(VIII) or (IX)
may also exist in their tautomeric forms. Such forms although not explicitly
indicated
in the above formula are intended to be included within the scope of the
present
invention.
Whenever used hereinafter, the term "compounds of formulae (I), (II), (TQ),
(IV), (V),
(VI), (VII), (VIII.) or (IX)" is meant to include also the pharmaceutically
acceptable
acid or base addition salts and all stereoisomeric forms.
~
Other farnesyl protein transferase inhibitors which can be employed in
accordance with
the present include Arglabin, perrilyl alcohol,.SCH-66336, 2(S)-[2(S)-[2(R)-
amino-3-
mercapto]propylamino-3(S)-methyl]-pentyloxy-3-phenylpropionyl-methionine
sulfone
(Merck); L778123, BMS 214662, Pfizer compounds A and B described above. These
compounds can be prepared, for example, by methods described in the relevant
patent
specifications identified above.
Farnesyl protein transferase inhibitors can be prepared and formulated into
pharmaceutical compositions by methods known in the art and in particular
according
to the methods described in the published patent specifications mentioned
herein;
for the compounds of formulae (I), (II) and (III) suitable
examples can be found in WO-97/21701. Compounds of formulae (IV), (V), and
(VI)
i- 25 can be prepared and formulated using methods described in WO 97/16443,
compounds
of formulae (VII) and (VIII) according to methods described in WO 98%40383 and
WO
98/49157 and compounds of formula (IX) according to methods described in WO
00/39082 respectively. To prepare the aforementioned pharmaceutical
compositions, a
therapeutically effective amount of the particular compound, optionally in
addition salt
form, as the active ingredient is combined in intimate admixture with a
pharmaceutically acceptable carrier, which may take a wide variety of forms
depending
= on the form of preparation desired for administration. These pharmaceutical
compositions are desirably in unitary dosage form suitable, preferably, for
systemic
= administration such as oral, percutaneous, or parenteral administration; or
topical
administration such as via inhalation, a nose spray, eye drops or via a cream,
gel,
shampoo or the like. For example, in preparing the compositions in oral dosage
form,
any of the usual pharmaceutical media may be employed, such as, for example,
water,
glycols, oils, alcohols and the like in the case of oral liquid preparations
such as
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-24-
suspensions, syrups, elixirs and solutions; or solid carriers such as
starches, sugars,
kaolin, lubricants, binders, disintegrating agents and the like in the case of
powders,
pills, capsules and tablets. Because of their ease in administration, tablets
and capsules
represent the most advantageous oral dosage unit form, in which case solid
pharmaceutical carriers are obviously employed. For parenteral compositions,
the
carrier will usually comprise sterile water, at least in large part, though
other
ingredients, for example, to aid solubility, may be included. Injectable
solutions, for
example, may be prepared in which the carrier compri.ses saline solution,
glucose
solution or a mixture of saline and glucose solution. Injectable solutions
containing
compounds of formula (I) may be formulated in an oil for prolonged action.
Appropriate oils for this purpose are, for example, peanut oil, sesame oil,
cottonseed
oil, corn oil, soy bean oil, synthetic glycerol esters of long chain fatty
acids and
mixtures of these and other oils. Injectable suspensions may also be prepared
in which
case appropriate liquid carriers, suspending agents and the like may be
employed. In
the compositions suitable for percutaneous administration, the carrier
optionally
comprises a penetration enhancing agent and/or a suitable wettable agent,
optionally
combined with suitable additives of any nature in minor proportions, which
additives
do not cause any significant deleterious effects on the skin. Said additives
may
facilitate the administration to the skin and/or may be helpful for preparing
the desired
compositions. These compositions may be administered in various ways, e.g., as
a
transdermal patch, as a spot-on or as an ointment. As appropriate compositions
for
topical application there may be cited all compositions usually employed for
topically
administering drugs e.g. creams, gellies, dressings, shampoos, tinctures,
pastes,
ointments, salves, powders and the like. Application of said compositions may
be by
aerosol, e.g. with a propellent such as nitrogen, carbon dioxide, a freon, or
without a
propellent such as a pump spray, drops, lotions, or a semisolid such as
ackened
composition which can be applied by a swab. In particular, semisolid
compositions
such as salves, creams, gellies, ointments and the like will conveniently be
used.
It is especially advantageous to formulate the aforementioned pharmaceutical
compositions in dosage unit form for ease of administration and uniformity of
dosage.
Dosage unit form as used in the specification and claims herein refers to
physically
discrete units suitable as unitary dosages, each unit containing a
predetermined quantity
of active ingredient calculated to produce the desired therapeutic effect in
association
with the required pharmaceutical carrier. Examples of such dosage unit forms
are
tablets (including scored or coated tablets), capsules, pills, powder packets,
wafers,
injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the
like, and
segregated multiples thereof.
CA 02396865 2008-03-27
WO 01/56552 PCT/EP01/01032
-25-
Preferably, a therapeutically effective amount of the pharmaceutical
composition
comprising a farnesyl protein transferase inhibitor is administered orally or
parenterally.
Said therapeutically effective amount is the amount that effectively prevents
growth or
reduces the size of breast cancer tumors in patients. On the basis of the
current data, it
appears that a pharmaceutical composition comprising a compound of formula
(I), (II),
(III), (IV), (V), (VI), (VII), (VIII) or (IX), and in particular (+)-
6.[amino(4-
chlorophenyl) (1-methyl-lH-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-
2(1H)-
quinolinone (compound 75) as the active ingredient can be administered orally
in an
amount of from 10 to 1500 mg daily, either as a single dose or subdivided into
more
than one dose. A preferred amount ranges from 100 to 1,000 mg daily. A
particularly
~ preferred dosage for such a compound is 300mg administered twice daily. This
treatment can be given either continuously or intermittently in cycles of 3-4
weeks with
treatment given for 1-21 days per cycle.
Suitable dosages for the compounds Arglabin (W098/28303), perrilyl alcohol (WO
99/45712), SCH-66336 (US 5,874,442), L778123 (WO 00/01691), 2(S)-[2(S)-[2(R)-
amino-3-mercapto]propylamino-3 (S)-methyl]-pentyloxy-3-phenylpropionyl-
methionine
sulfone (W094/10138), BMS 214662 (WO 97/30992), Pfizer compounds A and B
(WO 00/12499 and WO 00/12498) are given in the aforementioned patent
specifications
or are known to or can be readily determined
by a person skilled in the art.
In relation to perrilyl alcohol, the medicament may be administered 1-4g per
day per
1501b human patient. Preferably, 1-2 g per day per 1501b human patient. SCH-
66336
typically may be administered in a unit dose of about 0.1 mg to 100 mj, more
preferably
from about 1 mg to 300 mg according to the particular application. Compounds
L778123 and 2(S)-[2(S)-[2(R)-amino-3-mercapto]propylamino-3(S)-methyl]-
pentyloxy-
3-phenylpropionyl-methionine sulfone may be administered to a human patient in
an
amount between about 0.1 mg/kg of body weight to about 20 mg/kg of body weight
per
day, preferably between 0.5 mg/kg of bodyweight to about 10 mg/kg of body
weight per
= day-.
Pfizer compounds A and B may be administered in dosages ranging from about 1.0
mg
up to about 500 mg per day, preferably from about 1 to about 100 mg per day in
single
or divided (i.e. multiple) doses. Therapeutic compounds will ordinarly be
administered
in daily dosages ranging from about 0.01 to about 10 mg per kg body weight per
day, in
single or divided doses.
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-26-
BMS 214662 may be administered in a dosage range of about 0.05 to 200
mg/kg/day,
preferably less than 100 mg/kg/day in a single dose or in 2 to 4 divided
doses.
The above famesyl trasferase inhibitor may be used in combination with one or
more
other treatments for advanced breast cancer especially endocrine therapy such
as an anti-
estrogen agent such as an estrogen receptor antagonist or a selective estrogen
receptor
modulator or an aromatase inhibitor. A particularly preferred estrogen
receptor antagonist
is tamoxifen which has previously been widely used in the treatment of breast
cancer.
Other estrogen receptor antagonists or selective estrogen receptor modulators
include
toremifene, droloxifene, faslodex and raloxifene. Examples of aromatase
inhibitors or
inactivators include exemestane, anastrozole, letrazole and vorozole. Other
anti-cancer
agents which may be employed include platinum coordination compounds for
example
cisplatin or carboplatin, taxane compounds for example paclitaxel or
docetaxel,
camptothecin compounds for example irin6tecan or topotecan, anti-tumor vinca
alkaloids
for example vinblastine, vincristine or vinorelbine, anti-tumor nucleoside
derivatives for
example 5-fluorouracil, gemcitabine or capecitabine, nitrogen mustard or
nitrosourea
alkylating agents for example cyclophosphamide, chlorambucil, carmustine or
lomustine,
anti-tumor anthracycline derivatives for example daunorubicin, doxorubicin,
idarubicin or
epirubicin; HER2 antibodies for example trastzumab; and anti-tumor
podophyllotoxin
derivatives for example etoposide or teniposide.
The farnesyl transferase inhibitor and the further anti-cancer agent may be
administered
simultaneously (e.g. in separate or unitary compositions) or sequentially in
either order.
In the latter case, the two compounds will be administered within a period and
in an
amount and manner that is sufficient to ensure that an advantageous or
synergistic
effect is achieved. It will be appreciated that the preferred method and order
of
administration and the respective dosage amounts and regimes for each
component of
the combination will depend on the particular farnesyl transferase inhibitor
and further
anti-cancer agents being administered, their route of administration, the
particular
tumor being treated and the particular host being treated. The optimum method
and
order of administration and the dosage amounts and regime can be readily
determined
by those skilled in the art using conventional methods and in view of the
information
set out herein.
CA 02396865 2002-07-08
WO 01/56552 PCT/EP01/01032
-27-
Clinical Study
Compound 75 above, namely (+)-6-[amino(4-chlorophenyl) (1-methyl-lFl-imidazol-
5-
yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone was tested in
patients with
advanced breast cancer as described in the following account of a clinical
study.
The clinical study involved 27 patients with advanced breast cancer. The
median age of
the patients was 59 years (range 35-80 years). Adjuvant chemo and/or endocrine
therapy had been received by 15 and 16 patients respectively. Prior therapy
for
advanced disease included second-line hormonal therapy in 18 (67%) patients
and/or
one chemotherapy regimen only in 14 (52%) patients. Treatment was well
tolerated,
with myelosuppression the most frequent and dose-limiting toxicity. The first
6 patients
treated with 400 mg of compound 75 b.i.d. developed grade 3/4 neutropenia
after a
median of 26 days; 5 were re-treated with dose reduction following neutrophil
recovery
without further haematological toxicity. The subsequent 21 patients received
300 mg of
compound 75 b.i.d.; 6 (29%) developed grade 3/4 neutropenia after a median of
32
days, with one episode of fever. Neutrophil recovery occurred over 1-2 weeks
in all
cases. Thrombocytopenia (grade 3) occurred in 3(11%) patients. Non-
haematological
toxicities included: grade 2/3 parasthesia/numbness in 7 (26%) patients
occurring after
a median of 10 weeks therapy; grade 2/3 diarrhoea in 3 (11%) patients; skin
rash in 3
(11%) ; fatigue in 8(28%). 26 patients were able to be evaluated for tumour
response; 8
withdrew early (<12 weeks) due to either progression of disease and/or
toxicity while
18 patients received at least 3 months treatment (range 12-36+ weeks). Tumour
shrinkage of at least 50% in volume was seen in 3 (12%) patients, sites of
response
included liver, lung, lymph nodes and skin nodules. A further 9 (35%) patients
had
stable disease, i.e. no progression of tumour growth, at the 3 month
evaluation. These
results demonstrated that compound 75 has clinical activity in advanced bieast
cancer.
